Clinical Trial News

PetVivo partners with Orthobiologic Innovations (OBI) to pursue clinical trials of Spryng with OsteoCushion Technology for osteoarthritis in dogs. The injectable device aims to replicate natural joint cartilage, with initial trials focusing on elbow and stifle issues. OBI's expertise in regenerative medicine will support product development and market expansion.

RMC-6236, a non-covalent pan-RAS(ON) inhibitor by Revolution Medicines, shows efficacy in 'undruggable' RAS mutant tumors via a 'tri-complex' mechanism involving cyclophilin A. AACR 2024 meeting presentation covers its discovery, preclinical profile, and clinical updates.

Genentech's fenebrutinib, a non-covalent BTK inhibitor in Ph. III, showed significant CNS exposure and reduced new brain lesions in Ph. II for relapsing MS. It is the only reversible BTK inhibitor in Ph. III for MS, potentially differentiating on safety from covalent inhibitors.

Durvalumab showed consistent PFS and OS benefits vs placebo in LS-SCLC subgroups, regardless of prior PCI and concurrent CRT use, supporting its role as the new standard of care.

Resmetirom (REZDIFFRA™) became the first FDA-approved treatment for NASH on Mar. 14th, 2024. This oral, liver-targeting THR-β-selective agonist, discovered at Roche Nutley, was highlighted as Molecule of the Month in Dec. 2022 and is a 2023 Molecule of the Year nominee.

Tempus AI announced four abstracts accepted for ESMO Congress 2024, focusing on AI's impact on clinical trials, ctDNA monitoring, genomic profiling in lung cancer, and RAS/BRAF mutations in MSI/dMMR colorectal cancers.

Nuvalent's NVL-520, an oral, brain-penetrant, TRK-sparing ROS1 kinase inhibitor, entered Ph. II of ARROS-1 trial for advanced ROS1-positive NSCLC, showcasing potential best-in-class profile, addressing off-target toxicity, and innovative synthetic route.

FDA approves Ocrevus Zunovo™, the first twice-a-year 10-minute subcutaneous injection for relapsing and progressive multiple sclerosis, offering more treatment options based on individual needs.

CheckMate 9ER trial data shows cabozantinib plus nivolumab improves PFS, OS, and ORR in RCC, similar to other TKI/immunotherapy combinations, though favorable-risk patients see less benefit. Combination regimens are more tolerable than sunitinib, with potential post-discontinuation benefits.

Dr. Barbara Pistilli presents encouraging phase II ICARUS-BREAST01 results for patritumab deruxtecan, a new antibody-drug conjugate for metastatic breast cancer, showing a 53.5% response rate and 9.4 months median progression-free survival. The study identifies factors influencing response, suggesting potential as a new therapy for advanced hormone-dependent breast cancer.